Aktie A2QF35 PRIVETERRA ACQUISITION CORP. II
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Priveterra Acquisition Corp. II

Aktien

A2QF35

US8765451047

PMGM

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:30:00 16.04.2024 		% 5 Tage % 1. Jan.
11,21 USD +1,72 % Intraday Chart für Priveterra Acquisition Corp. II 0,00 % +2,00 %
2023 Priveterra Acquisition Corp. II meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI
2023 Priveterra Acquisition Corp. II meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
AEON Biopharma Announces Redemption of Public Warrants - March 29, 2024
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
AEON Biopharma Announces Redemption of Public Warrants
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
Priveterra Acquisition Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
AEON Biopharma Reports Third Quarter 2023 Financial Results
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
Priveterra Acquisition Corp. II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Tastemaker Acquisition Corp. has Changed its Name to Priveterra Acquisition Corp. II
Tastemaker Acquisition Corp. Announces the Resignation of Christopher Bradley as Chief Financial Officer
Tastemaker Acquisition Corp. Announces Board Changes
Tastemaker Acquisition Corp. Announces CEO Changes
Tastemaker SPAC calls off nearly $1 bln planned merger with Quality Gold
Tastemaker Acquisition : Announces Termination of Business Combination Agreement - Form 8-K
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QF35 Aktie
  4. Nachrichten Priveterra Acquisition Corp. II
  5. Andere Sprachen